does anyone have access to the results of the 'peptide aldehyde proteasome inhibitor PSI topical' results? I can't for the life of me get access to it. this is all i got.
Two separate randomized clinical studies have been performed to determine the effects of the peptide aldehyde proteasome inhibitor PSI on hair follicles in subjects with male pattern baldness. The first was a phase I clinical study with an efficacy component in which 12 healthy Caucasian males were en- tered with intermediate hair loss (100–250 hairs/cm2 at sites of application) corresponding to types III-V male pattern baldness, as assessed on a modified Hamilton-Norwood scale. These subjects were examined by the technique of contrast-enhanced phototrichogram (CE-PTG) at weekly intervals of a marked 1 cm area of the scalp to which the compound was applied, with comparison to a corresponding area on the other side of the scalp, which received vehi- cle alone.5,6 The parameters measured included linear hair growth, and the numbers of anagen hairs, telogen hairs, and the anagen/telogen ratio. There was a statistically significant increase in each of the variables assessed of the subjects who completed the study following treatment with PSI, compared to vehicle.
In a separate randomized, double-blind Phase IIa clinical study 50 men with androgenetic alopecia (Norwood–Hamilton grades III–IV) received once-daily topical treatments of a 2% solution of the active compound or placebo. The compound was administered for two 14-day treatment cycles with a 4-week rest period in between treatments. Hair growth was measured using an objective photographic, computer-based analysis for up to 24 weeks after initiation of therapy. The parameters assessed were hair density (total hair count), terminalMUNDY et al. 301 hair density (hair count of hairs greater than 40 m), and cumulative hair thickness. The 2% solution demonstrated a statistically significant beneficial effect on hair density (P = 0.04), and cumulative hair thickness (P = 0.02). The peak effects occurred 8 weeks following the second 2-week treatment cycle. Importantly, there was an increased number of terminal hairs (defined as >40 m). There were no serious adverse events observed.
The results from both of these separate clinical studies confirm that a proteasome inhibitor applied topically to the scalp stimulates anagen induction and induces hair growth in men with male pattern baldness. The same com- pound stimulates osteoblast differentiation and bone growth, presumably using similar molecular mechanisms.
